Breaking News Instant updates and real-time market news.

QTT

Qutoutiao

$8.84

-0.16 (-1.78%)

, MTCH

Match Group

$57.21

-0.67 (-1.16%)

08:45
04/15/19
04/15
08:45
04/15/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Qutoutiao (QTT) 40.20% +4.99, Match Group (MTCH) 0.71% +0.40, CannTrust Holdings (CTST) 18.28% +0.05, iShares MSCI China (MCHI) 0.41% +0.03, ProShares UltraPro Short Dow 30 (SDOW) 3.33% +0.02, Enphase Energy (ENPH) 4.40% +0.01, JD.com (JD) 0.89% +0.01, Novavax (NVAX) 3.64% +0.01, and Ocwen Financial (OCN) 0.29% +0.01.

QTT

Qutoutiao

$8.84

-0.16 (-1.78%)

MTCH

Match Group

$57.21

-0.67 (-1.16%)

CTST

CannTrust

$7.16

0.15 (2.14%)

ENPH

Enphase Energy

$9.94

0.145 (1.48%)

JD

JD.com

$30.57

0.37 (1.23%)

NVAX

Novavax

$0.54

-0.0252 (-4.44%)

OCN

Ocwen

$2.00

0.005 (0.25%)

  • 08

    May

  • 15

    May

  • 28

    May

QTT Qutoutiao
$8.84

-0.16 (-1.78%)

03/06/19
KEYB
03/06/19
DOWNGRADE
KEYB
Sector Weight
Qutoutiao downgraded to Sector Weight from Overweight at KeyBanc
02/20/19
DBAB
02/20/19
DOWNGRADE
DBAB
Hold
Qutoutiao downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim downgraded Qutoutiao to Hold saying the risk/reward is balanced at current share levels.
02/15/19
UBSW
02/15/19
DOWNGRADE
Target $13.5
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
UBS analyst Jerry Liu downgraded Qutoutiao to Neutral from Buy, telling investors in a research note that the share price has almost tripled since mid-December, possibly attributable to the strong momentum of the company's user expansion as well as Midu's initial success. Liu, who raised his price target to $13.50 from $11, says Qutoutiao's current price implies 2.8x2019E P/S, which he thinks represents a fair risk-reward balance between its user growth potential and margin pressure.
02/15/19
UBSW
02/15/19
DOWNGRADE
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
MTCH Match Group
$57.21

-0.67 (-1.16%)

02/11/19
JPMS
02/11/19
NO CHANGE
Target $250
JPMS
Overweight
IAC price target raised to $250 from $235 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for IAC (IAC) to $250 following the company's Q4 results and initial 2019 guidance. The analyst remains positive on the shares with increased confidence in the trajectory of Vimeo and Dotdash offsetting his slightly lowered Angi Homeservices (ANGI) estimates. Anmuth continues to prefer IAC over Match Group (MTCH) and keeps an Overweight rating on the shares.
02/08/19
RHCO
02/08/19
NO CHANGE
Target $54
RHCO
Hold
Match Group price target raised to $54 from $47 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Match Group to $54 after its strong Q4 results, saying Tinder was again the "main driver of growth" and its success in "optimizing the platform to mobilize a significantly higher number of new subs to offset the pick-up in churn from older cohorts." The analyst also keeps his Hold rating on the shares citing valuation, with Match Group trading at 8.9-times enterprise value to expected revenues, and due to expected decline in FY19 aggregate subscriptions.
04/03/19
JEFF
04/03/19
NO CHANGE
Target $64
JEFF
Buy
Jefferies sees Match Group shares grinding, not flying, higher
While difficult to maintain the 30% growth experienced in 2018, Match Group should see sustainable mid to high teen revenue growth and high 30% margins going forward, Jefferies analyst Brent Thill tells investors in a research note. However, with the stock up 32% year-to-date, "further multiple expansion may prove difficult at these levels," adds the analyst. Nonetheless, Thill trusts Match's "history of quarterly execution" and the long-term "tailwinds at play. He expects the stock "to grind higher rather than fly higher" and keeps a Buy rating on the name with a $64 price target. It remains a top mid cap pick at Jefferies.
02/27/19
JEFF
02/27/19
NO CHANGE
Target $64
JEFF
Buy
Match Group remains a top mid cap pick despite recent rally at Jefferies
The Spring Break mode builds off of Tinder U and helps expand Match Group's reach into the college demographic, Jefferies analyst Brent Thill tells investors in a research note. While some will argue that Tinder growth is tapped out, the amount of paying subs, 4.3M, is still fewer than the incoming U.S. freshmen class, the analyst points out, whose data checks show continued strength. Thill says Match Group remains one of his top mid cap picks despite the 29% rally year-to-date. The analyst keeps a Buy rating on the shares with a $64 price target.
CTST CannTrust
$7.16

0.15 (2.14%)

ENPH Enphase Energy
$9.94

0.145 (1.48%)

03/19/19
RAJA
03/19/19
DOWNGRADE
RAJA
Underperform
Enphase Energy downgraded to Underperform from Market Perform at Raymond James
03/19/19
03/19/19
DOWNGRADE

Underperform
Enphase Energy downgraded to Underperform on valuation Raymond James
As previously reported, Raymond James downgraded Enphase Energy to Underperform from Market Perform. Analyst Pavel Molchanov said shares have doubled year-to-date despite margin risks ahead.
03/25/19
FBCO
03/25/19
INITIATION
Target $10
FBCO
Neutral
Enphase Energy initiated with a Neutral at Credit Suisse
Credit Suisse analyst Maheep Mandloi started coverage of Enphase Energy with a Neutral rating and a $10 price target on the shares. The analyst notes that Enphase Energy's restructuring over the last two years has paid off with gross margins now back up to management's Q4 target of about 30%. Further, the company's products are primarily used in the U.S. residential solar industry, and hence less affected by competition in international markets, he adds. Nonetheless, Mandloi believes this is already priced in at current levels.
02/21/19
COWN
02/21/19
NO CHANGE
Target $9
COWN
Outperform
Enphase Energy price target raised to $8.50 from $6.75 at Cowen
Cowen analyst Jeffrey Osborne raised his price target on Enphase Energy to $8.50 from $6.75 ahead of Q4 results. The analyst believes both the results and guidance will be in-line with expectations, but he said long lead times due to component supply tightness will impede growth in the near term. Osborne reiterated his Outperform rating on Enphase Energy shares.
JD JD.com
$30.57

0.37 (1.23%)

01/31/19
UBSW
01/31/19
DOWNGRADE
UBSW
Neutral
JD.com downgraded to Neutral from Buy at UBS
03/01/19
BNCH
03/01/19
NO CHANGE
Target $34
BNCH
Buy
JD.com price target raised to $34 after 'solid quarter' at Benchmark
Benchmark analyst Fawne Jiang said JD.com reported "solid" Q4 results, with upside driven by healthy core e-commerce growth as well as improving margin trends. Despite ongoing macro concerns, Q1 revenue guidance and full year margin guidance were above expectations, said Jiang, who raised her price target on JD.com shares to $34 from $31 and keeps a Buy rating on the stock.
03/01/19
LYON
03/01/19
UPGRADE
Target $31
LYON
Outperform
JD.com upgraded to Outperform from Underperform at CLSA
CLSA analyst Elinor Leung upgraded JD.com to Outperform from Underperform after the company reported "weak," but better than expected, top-line growth in Q4 along with a margin beat on better cost control. 2019 margins are expected to improve further, noted Leung, who raised the firm's price target on JD.com shares to $31 from $24.
04/15/19
MSCO
04/15/19
NO CHANGE
Target $28
MSCO
Equal Weight
JD.com price target raised to $28 from $25 at Morgan Stanley
Morgan Stanley analyst Grace Chen said she expects in-line to better than consensus results from JD.com in Q1 given her forecast for in-line or better than consensus Q1 margins and sales at the midpoint of guidance. The analyst, who expects the investment debate for JD.com to shift from margins to tampering sales growth, is cautious about intense competition. She keeps an Equal Weight rating on the stock but raised her price target to $28 from $25.
NVAX Novavax
$0.54

-0.0252 (-4.44%)

03/01/19
HCWC
03/01/19
NO CHANGE
Target $2
HCWC
Buy
'Strong' investment thesis remains for buying Novavax, says H.C. Wainwright
A "strong" investment thesis remains for buying Novavax shares, H.C. Wainwright analyst Vernon Bernardino tells investors in a research note. He reiterates a Buy rating on the stock with a $2 price target. Novavax closed yesterday down 67%, or $1.42, to 71c. ResVax, despite the failed Phase 3 study, showed efficacy in hospitalizations and lower respiratory tract infections with severe hypoxemia, which are likely the most clinically relevant measures over the first 180 days of life in infants in the study, Bernardino contends. The analyst looks for discussions with the FDA and European regulators, which are expected in the next 90 days, to be positive for the completion of ResVax's "pathway to regulatory approval."
03/04/19
RILY
03/04/19
NO CHANGE
Target $1.75
RILY
Buy
Novavax flu vaccine potential being overlooked, say B. Riley FBR
Investors did not interpret Novavax's trial results for its respiratory syncytial virus vaccine properly and are overlooking its flu vaccine potential, B. Riley FBR analyst George Zavoico tells investors in a research note. Prepare would have been a successful registrational Phase III trial if it had incorporated some minor design changes understood now but unknown when the trial was planned, says the analyst. He points out that Novavax will meet with the FDA in the next 30-90 days to present a case for accepting a biologics license application for review this year, based on "robust" vaccine efficacy reported for clinically meaningful secondary endpoints. Zavoico ascribes a low probability to this outcome, but notes it would be a game-changer for Novavax if the FDA makes a decision to review a ResVax BLA, based only on the available data set. He lowered his price target for the shares to $1.75 from $10 and keeps a Buy rating on the name.
03/19/19
SBSH
03/19/19
NO CHANGE
Target $1.25
SBSH
Buy
Citi cuts Novavax target to $1.25, sees three reasons to keep Buy
Citi analyst Joel Beatty lowered his price target for Novavax to $1.25 from $3.50 but maintains a Buy rating on the shares. While the recent failure of the Phase 3 respiratory syncytial virus vaccine trial was a "major setback" for the company, three potential upside opportunities collectively make the stock a Buy, Beatty tells investors in a research note. These include an accelerated approval pathway being confirmed by the FDA for NanoFlu, a scenario the analyst believes is "slightly more likely than not," a ResVax partnership is announced, and/or ResVax receiving approval in Europe.
03/19/19
HCWC
03/19/19
NO CHANGE
Target $2
HCWC
Buy
H.C. Wainwright sees pathway for Novavax approval, keeps $2 price target
Following the company's Q4 results and business update, H.C. Wainwright analyst Vernon Bernardino continues to believe a "strong investment thesis remains" for buying Novavax shares. The Prepare trial showed ResVax was safe, and importantly, resulted in clinically meaningful outcomes, Bernardino tells investors in a research note. While the stock remains down 76% from its closing price of $2.13 prior to the Prepare results, prospects for discussions with the FDA and European Medicines Agency, which are expected in the next 90 days, are positive, contends the analyst. He believe ResVax's pathway to approval is "under-appreciated" and would be a buyer of the stock. Bernardino keeps a Buy rating on Novavax with a $2.00 price target. The stock in midday trading is down fractionally at 52c.
OCN Ocwen
$2.00

0.005 (0.25%)

11/30/18
BTIG
11/30/18
INITIATION
BTIG
Neutral
Ocwen initiated with a Neutral at BTIG
As reported earlier, BTIG analyst Giuliano Bologna initiated Ocwen with a Neutral rating as part of his broader research note into Mortgage Servicers. The analyst notes that in spite of the rising interest rate tail risk, the stock does not represent an "attractive opportunity currently due to the wide range of potential outcomes during the company's turnaround". Bologna adds that the range of outcomes should narrow and his investment thesis will become clearer as Ocwen progresses toward its goals of "cutting costs, integrating the PHH Corp (PHH) acquisition and boarding current loans onto the Black Knight (BKI) LoanSphere.
11/29/18
BTIG
11/29/18
INITIATION
BTIG
Neutral
Ocwen initiated with a Neutral at BTIG
BTIG analyst Guiliano Anderes-Bologna started Ocwen Financial with a Neutral rating.

TODAY'S FREE FLY STORIES

VTR

Ventas

$69.65

1.05 (1.53%)

21:28
06/19/19
06/19
21:28
06/19/19
21:28
Upgrade
Ventas rating change at Stifel »

Stifel upgrades to Ventas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Apple initiated at Deutsche Bank »

Apple initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

DELL

Dell Technologies

$53.39

1.88 (3.65%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Dell Technologies initiated at Deutsche Bank »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HPQ

HP Inc.

$20.63

0.1 (0.49%)

21:21
06/19/19
06/19
21:21
06/19/19
21:21
Initiation
HP Inc. initiated at Deutsche Bank »

HP Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

GNCA

Genocea

$3.84

-1.32 (-25.58%)

21:18
06/19/19
06/19
21:18
06/19/19
21:18
Syndicate
Genocea 10M share Secondary priced at $3.50 »

SVB Leerink and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

21:15
06/19/19
06/19
21:15
06/19/19
21:15
Syndicate
Personalis 7.922M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CYRX

Cryoport

$18.62

-0.08 (-0.43%)

21:13
06/19/19
06/19
21:13
06/19/19
21:13
Syndicate
Cryoport 3.75M share Spot Secondary priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VTR

Ventas

$69.65

1.05 (1.53%)

20:41
06/19/19
06/19
20:41
06/19/19
20:41
Upgrade
Ventas rating change at Stifel »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$137.94

-0.29 (-0.21%)

20:27
06/19/19
06/19
20:27
06/19/19
20:27
Downgrade
Hershey rating change at Piper Jaffray »

Hershey downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$23.64

-0.3 (-1.25%)

, DRI

Darden

$117.55

-0.39 (-0.33%)

20:25
06/19/19
06/19
20:25
06/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.64

-0.3 (-1.25%)

DRI

Darden

$117.55

-0.39 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

DAL

Delta Air Lines

$56.38

0.33 (0.59%)

20:08
06/19/19
06/19
20:08
06/19/19
20:08
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta working on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

, SPX

S&P 500

$0.00

(0.00%)

20:00
06/19/19
06/19
20:00
06/19/19
20:00
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump not planning to…

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARZGY

Generali

$0.00

(0.00%)

19:22
06/19/19
06/19
19:22
06/19/19
19:22
Downgrade
Generali rating change at JPMorgan »

Generali downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GO

Grocery Outlet

$0.00

(0.00%)

19:00
06/19/19
06/19
19:00
06/19/19
19:00
Syndicate
Grocery Outlet 17.19M share IPO priced at $22.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

WIX

Wix.com

$145.83

1.19 (0.82%)

18:57
06/19/19
06/19
18:57
06/19/19
18:57
Hot Stocks
Wix.com CEO: Q1 was very good for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

, ORCL

Oracle

$52.69

-0.19 (-0.36%)

18:44
06/19/19
06/19
18:44
06/19/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

ORCL

Oracle

$52.69

-0.19 (-0.36%)

JSYN

Jensyn Acquisition

$5.00

-5.02 (-50.10%)

ABEO

Abeona Therapeutics

$4.90

-0.09 (-1.80%)

PIR

Pier 1 Imports

$0.67

-0.0059 (-0.87%)

SCS

Steelcase

$17.80

0.235 (1.34%)

LAND

Gladstone Land

$12.29

0.39 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jun

  • 26

    Jun

  • 26

    Jun

  • 10

    Jul

  • 20

    Jun

TMUS

T-Mobile

$78.28

1.79 (2.34%)

, S

Sprint

$7.46

0.24 (3.32%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Periodicals
T-Mobile readies for Boost auction if Dish talks fall through, Reuters says »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$78.28

1.79 (2.34%)

S

Sprint

$7.46

0.24 (3.32%)

DISH

Dish

$38.90

-0.18 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Hot Stocks
Zebra Technologies Chief of Product sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:23
06/19/19
06/19
18:23
06/19/19
18:23
Hot Stocks
Zebra Technologies CEO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$250.25

4.6 (1.87%)

, DVA

DaVita

$51.27

1.51 (3.03%)

18:13
06/19/19
06/19
18:13
06/19/19
18:13
Hot Stocks
FTC approves UnitedHealth's acquisition of DaVita Medical with conditions »

Healthcare provider and…

UNH

UnitedHealth

$250.25

4.6 (1.87%)

DVA

DaVita

$51.27

1.51 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SRRK

Scholar Rock

$17.11

-2.835 (-14.21%)

18:11
06/19/19
06/19
18:11
06/19/19
18:11
Syndicate
Scholar Rock 3M share Secondary priced at $15.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

QDEL

Quidel

$58.80

1.7 (2.98%)

18:01
06/19/19
06/19
18:01
06/19/19
18:01
Hot Stocks
Quidel receives 510k clearance for Triage TOX Drug Screen »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.39

1.88 (3.65%)

, HPQ

HP Inc.

$20.63

0.1 (0.49%)

17:59
06/19/19
06/19
17:59
06/19/19
17:59
Periodicals
Dell, HP, Intel, Microsoft express opposition to Trump tariffs, Bloomberg says »

Dell Technologies (DELL),…

DELL

Dell Technologies

$53.39

1.88 (3.65%)

HPQ

HP Inc.

$20.63

0.1 (0.49%)

INTC

Intel

$47.08

-0.29 (-0.61%)

MSFT

Microsoft

$135.63

0.43 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 06

    Aug

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Oracle says 20% of Autonomous Database customers new to company »

Says plans to launch free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CB

Chubb

$149.48

1.37 (0.92%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Chubb CEO sells 215.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.